The entire playing field fit inside his shoes. From his feet it sprouted and grew. Alfredo Di Stefano ran and re-ran the field from net to net. He would change flanks and rhythm with the ball, from a lazy trot to an unstoppable cyclone; without the ball he’d evade his marker to gain open space, seeking air whenever a play would get choked off. He never stood still. Holding his head high, he could see the entire playing field and cross it at a gallop to pry open the defense and launch the attack. He was there at the beginning, the during and the end of every scoring play, and he scored goals of all colors: Watch out, watch out,[…]

“Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product.” ~ Marijn Dekkers, Bayer Chief Executive Officer The global pharma industry’s reputation is getting worse, and is only slightly better than health insurers. Statements, like the one above, do not help. This statement, made by none less than the CEO of a major MNC pharmaceutical player, while being incredibly insensitive, is also alarmingly honest. At ~$12bn and double digit growth the Indian pharma market seems incredibly attractive. However, according to industry estimates,[…]

Indian pharmaceutical companies cannot be judged by American standards. – GN Singh, Drug Controller General of India [source]

If you are looking for one reason for the mess that the Indian pharma industry is in, you do not need to look further than the statement above. This is a statement made by the head of the body responsible for ensuring the quality of drugs manufactured and sold in the country.